Your browser doesn't support javascript.
loading
Multiomics Characterization of Low-Grade Serous Ovarian Carcinoma Identifies Potential Biomarkers of MEK Inhibitor Sensitivity and Therapeutic Vulnerability.
Shrestha, Raunak; Llaurado Fernandez, Marta; Dawson, Amy; Hoenisch, Joshua; Volik, Stanislav; Lin, Yen-Yi; Anderson, Shawn; Kim, Hannah; Haegert, Anne M; Colborne, Shane; Wong, Nelson K Y; McConeghy, Brian; Bell, Robert H; Brahmbhatt, Sonal; Lee, Cheng-Han; DiMattia, Gabriel E; Le Bihan, Stephane; Morin, Gregg B; Collins, Colin C; Carey, Mark S.
Affiliation
  • Shrestha R; Vancouver Prostate Centre, Vancouver, British Columbia, Canada.
  • Llaurado Fernandez M; Department of Urologic Sciences, University of British Columbia, Vancouver, British Columbia, Canada.
  • Dawson A; Department of Radiation Oncology, University of California San Francisco, San Francisco, California.
  • Hoenisch J; Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of British Columbia, Vancouver, British Columbia, Canada.
  • Volik S; Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of British Columbia, Vancouver, British Columbia, Canada.
  • Lin YY; Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of British Columbia, Vancouver, British Columbia, Canada.
  • Anderson S; Vancouver Prostate Centre, Vancouver, British Columbia, Canada.
  • Kim H; Vancouver Prostate Centre, Vancouver, British Columbia, Canada.
  • Haegert AM; Department of Urologic Sciences, University of British Columbia, Vancouver, British Columbia, Canada.
  • Colborne S; Vancouver Prostate Centre, Vancouver, British Columbia, Canada.
  • Wong NKY; Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of British Columbia, Vancouver, British Columbia, Canada.
  • McConeghy B; Vancouver Prostate Centre, Vancouver, British Columbia, Canada.
  • Bell RH; Michael Smith Genome Sciences Centre, BC Cancer Agency, Vancouver, British Columbia, Canada.
  • Brahmbhatt S; Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of British Columbia, Vancouver, British Columbia, Canada.
  • Lee CH; Department of Pathology & Laboratory Medicine, BC Cancer Agency, Vancouver, British Columbia, Canada.
  • DiMattia GE; Vancouver Prostate Centre, Vancouver, British Columbia, Canada.
  • Le Bihan S; Vancouver Prostate Centre, Vancouver, British Columbia, Canada.
  • Morin GB; Vancouver Prostate Centre, Vancouver, British Columbia, Canada.
  • Collins CC; Department of Pathology & Laboratory Medicine, BC Cancer Agency, Vancouver, British Columbia, Canada.
  • Carey MS; Translational Ovarian Cancer Research Program, London Health Science Centre, London, Ontario, Canada.
Cancer Res ; 81(7): 1681-1694, 2021 04 01.
Article in En | MEDLINE | ID: mdl-33441310
Subject(s)
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Ovarian Neoplasms / Cystadenocarcinoma, Serous / Mitogen-Activated Protein Kinase Kinases / Protein Kinase Inhibitors / Biomarkers, Pharmacological Type of study: Diagnostic_studies / Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Female / Humans Language: En Journal: Cancer Res Year: 2021 Type: Article Affiliation country: Canada
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Ovarian Neoplasms / Cystadenocarcinoma, Serous / Mitogen-Activated Protein Kinase Kinases / Protein Kinase Inhibitors / Biomarkers, Pharmacological Type of study: Diagnostic_studies / Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Female / Humans Language: En Journal: Cancer Res Year: 2021 Type: Article Affiliation country: Canada